Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Albumin Dialysis to Treat Patients With Hepatic Encephalopathy Using The Molecular Adsorbent Recirculating System (MARS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed written informed consent by patient or patient's legally appointed representative~2. Be at least 18 years of age; male or female~3. Have chronic end stage liver disease with worsening Hepatic Encephalopathy (Grades 3,4).~Exclusion Criteria:~1. Clinically significant bleeding from gastrointestinal or other site within the last 24 hours and requires 2 or more units of blood to maintain a stable hemoglobin level~2. Hemodynamically unstable or on vasopressor agents for blood pressure support (except for renal-dosed dopamine)~3. On acute or chronic hemodialysis or continuous renal replacement therapy (CRRT)~4. Pregnancy~5. Inability to obtain informed consent~6. Uncontrolled sepsis as defined by hemodynamic instability~7. Post-liver transplant~8. Fulminant hepatic failure~9. Irreversible brain damage as indicated by the neurologic examination and CT imaging~10. Endocarditis~11. Pulmonary edema~12. Massive aspiration pneumonia secondary to Hepatic Encephalopathy~13. Active alcohol consumption as determined by a positive blood ethanol level on enrollment/admission~14. Acute main portal vein thrombosis in patients with Hepatocellular Carcinoma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1: Standard Medical Therapy + MARS (Type: EXPERIMENTAL): Patients who were randomized to Group 1 received daily MARS treatments in addition to Standard Medical Therapy for 5 consecutive days.
- Group 2: Standard Medical Therapy Only (Type: ACTIVE_COMPARATOR): Patients who were randomized to Group 2 received standard medical treatment only.

Based on this trial design, predict the completion outcome and termination type (if applicable).